Literature DB >> 10485257

Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. European Concerted Action on Immunological and Virological Markers of HIV Disease Progression.

K S Froebel1, N G Pakker, F Aiuti, M Bofill, H Choremi-Papadopoulou, J Economidou, C Rabian, M T Roos, L P Ryder, F Miedema, G M Raab.   

Abstract

Lymphocyte proliferation is a widely used technique to assess immune competence. However, the technique is subject to a large degree of variation, some biological and some technical. In this study, the components of variation in whole blood proliferation assays were analysed over time, using both antibody and mitogenic stimulants. The levels of variation within individual samples, between individuals and between groups of individuals over time were examined. A method of transforming the data is proposed which reduces the coefficients of variation to an acceptable level, and which expresses individual results as a standardised count. This method overcomes the problem of different levels of absolute counts, it corrects for time sensitive errors and allows data from multiple laboratories to be pooled.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485257     DOI: 10.1016/s0022-1759(99)00082-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Culture and stimulation of tammar wallaby lymphocytes.

Authors:  L J Young; E M Deane
Journal:  Vet Res Commun       Date:  2007-01-23       Impact factor: 2.459

2.  Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.

Authors:  A Samri; C Durier; A Urrutia; I Sanchez; H Gahery-Segard; S Imbart; M Sinet; E Tartour; J-P Aboulker; B Autran; A Venet
Journal:  Clin Vaccine Immunol       Date:  2006-06

3.  Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.

Authors:  Hui Hu; Xinya Lu; Ling Tao; Bingke Bai; Zhenfeng Zhang; Yao Chen; Fangliang Zheng; Jianjun Chen; Ze Chen; Hanzhong Wang
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

4.  Steroidal Alkaloids as an Emerging Therapeutic Alternative for Investigation of Their Immunosuppressive and Hepatoprotective Potential.

Authors:  Naeem U Jan; Bashir Ahmad; Safdar Ali; Achyut Adhikari; Amjad Ali; Azra Jahan; Abid Ali; Hamid Ali
Journal:  Front Pharmacol       Date:  2017-03-21       Impact factor: 5.810

5.  Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine.

Authors:  Noton Kumar Dutta; Kaushiki Mazumdar; Byoung-Hee Lee; Min-Won Baek; Dong-Jae Kim; Yi-Rang Na; Sung-Hoon Park; Hyun-Kyoung Lee; Hiroaki Kariwa; Le Quynh Mai; Jae-Hak Park
Journal:  Immunol Lett       Date:  2008-04-08       Impact factor: 3.685

6.  Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.

Authors:  Rosangela Salerno-Gonçalves; Wilbur H Chen; Mark J Mulligan; Sharon E Frey; Jack T Stapleton; Wendy A Keitel; Jason Bailey; Eli Sendra; Heather Hill; Robert A Johnson; Marcelo B Sztein
Journal:  Clin Transl Immunology       Date:  2021-01-19

7.  Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

Authors:  Joseph W Kim; Marijo Bilusic; Christopher J Heery; Ravi A Madan
Journal:  Cancers (Basel)       Date:  2012-11-22       Impact factor: 6.639

8.  Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.

Authors:  Hui Hu; Xianqing Huang; Ling Tao; Yi Huang; Bao-An Cui; Hanzhong Wang
Journal:  Vaccine       Date:  2009-01-30       Impact factor: 3.641

9.  Diazepam leads to enhanced severity of orthopoxvirus infection and immune suppression.

Authors:  Hartwig P Huemer; Caroline Lassnig; Norbert Nowotny; Eveline U Irschick; Maria Kitchen; Marion Pavlic
Journal:  Vaccine       Date:  2010-07-24       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.